Year Founded
2019
Ownership
Private
Employees
~100
Therapeutic Areas
HematologyImmunology
Stage
Phase 1
Modalities
Autologous cell therapyGene therapy

ASC Therapeutics General Information

Received IND clearance for ASC618, a second-generation gene therapy for hemophilia A. The therapy shows 10-fold increase in Factor VIII biosynthesis and secretion compared to native human FVIII constructs in preclinical studies.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

ASC618
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to ASC Therapeutics's pipeline data

Book a demo

Key Partnerships

Expression Therapeutics

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

ASC Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view ASC Therapeutics's complete valuation and funding history, request access »

ASC Therapeutics Investors

SATAI Network
Investor Type: Venture Capital
Holding: Minority